Suppr超能文献

肿瘤细胞通过功能性凝血酶原酶组装产生凝血酶。

Tumor cell generation of thrombin via functional prothrombinase assembly.

作者信息

VanDeWater L, Tracy P B, Aronson D, Mann K G, Dvorak H F

出版信息

Cancer Res. 1985 Nov;45(11 Pt 1):5521-5.

PMID:4053025
Abstract

Prothrombinase affects the proteolytic conversion of prothrombin to thrombin and is the penultimate enzyme in the common coagulation pathway. Prothrombinase is a complex in which the proteinase, Factor Xa, a cofactor, Factor Va, and calcium are bound to a membrane surface to generate the active enzyme. Guinea pig line 1 and line 10 tumor cells, grown as primary cultures from ascites tumors or as cell lines in culture, provide a surface that interacts with coagulation Factor Va and Xa and with calcium ions to form this enzyme complex. Cultured human colorectal carcinoma cells (Colo 205) also participate in prothrombinase complex assembly and function. Prothrombinase generation was measured by following the kinetics of prothrombin conversion to thrombin. Thrombin generation was monitored continuously using the reversible thrombin inhibitor, dansylarginine N-(3-ethyl-1,5-pentanediyl)amide, which displays enhanced fluorescence upon binding to thrombin. Analyses of kinetic data indicate that the apparent dissociation constants (1-4 X 10(-10) mol/liter) and the number of Factor Va-Xa binding sites per tumor cell are comparable to values reported for human and bovine platelets, human lymphocytes, and monocytes. Guinea pig lymphocytes were also active, while erythrocytes were inactive, in the prothrombinase assay. Membrane vesicles, shed by guinea pig and human tumor cells into conditioned medium, also supported functional prothrombinase activity. Although earlier studies indicated that tumor cells may initiate coagulation, this is the first demonstration that tumor cells are competent to bring clotting to fruition by generating thrombin, a step essential to fibrin generation. These data suggest that tumor cells, in the presence of clotting initiators and appropriate coagulation factors, are sufficient to generate the fibrin deposited in solid tumors.

摘要

凝血酶原酶影响凝血酶原向凝血酶的蛋白水解转化,是共同凝血途径中的倒数第二个酶。凝血酶原酶是一种复合物,其中蛋白酶(因子Xa)、辅因子(因子Va)和钙结合到膜表面以产生活性酶。豚鼠1号线和10号线肿瘤细胞,从腹水肿瘤中作为原代培养物生长或在培养物中作为细胞系生长,提供了一个与凝血因子Va和Xa以及钙离子相互作用以形成这种酶复合物的表面。培养的人结肠癌细胞(Colo 205)也参与凝血酶原酶复合物的组装和功能。通过追踪凝血酶原转化为凝血酶的动力学来测量凝血酶原酶的生成。使用可逆凝血酶抑制剂丹磺酰精氨酸N-(3-乙基-1,5-戊二酰基)酰胺连续监测凝血酶的生成,该抑制剂在与凝血酶结合时显示出增强的荧光。动力学数据分析表明,表观解离常数(1 - 4×10⁻¹⁰摩尔/升)和每个肿瘤细胞上因子Va - Xa结合位点的数量与报道的人及牛血小板、人淋巴细胞和单核细胞的值相当。在凝血酶原酶测定中,豚鼠淋巴细胞也有活性,而红细胞无活性。豚鼠和人肿瘤细胞释放到条件培养基中的膜囊泡也支持功能性凝血酶原酶活性。尽管早期研究表明肿瘤细胞可能启动凝血,但这是首次证明肿瘤细胞能够通过生成凝血酶使凝血过程完成,而凝血酶是纤维蛋白生成所必需的一步。这些数据表明,在凝血启动剂和适当的凝血因子存在的情况下,肿瘤细胞足以产生沉积在实体瘤中的纤维蛋白。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验